<DOC>
	<DOCNO>NCT00100256</DOCNO>
	<brief_summary>The purpose study determine maximum dose safely tolerated experimental drug Rhenium Re 188 P2045 . This do first treat patient relatively low dos Rhenium Re 188 P2045 , observe closely assure bad side effect , increase dose confident safe .</brief_summary>
	<brief_title>Rhenium Re 188 P2045 Patients With Lung Cancer Who Have Received Refused Receive Prior Chemotherapy</brief_title>
	<detailed_description>We want learn side effect profile Technetium Tc 99m P2045 Rhenium Re 188 P2045 observe closely receive drug conduct multiple test , well ask feel . We want also learn benefit , term lung cancer tumor reduction , result treatment Rhenium Re 188 P2045 . This study previously post Berlex , Inc. Berlex , Inc. rename Bayer HealthCare Pharmaceuticals , Inc.Bayer HealthCare Pharmaceuticals , Inc.is sponsor trial .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<mesh_term>Neoplasm Recurrence , Local</mesh_term>
	<criteria>Has histologically cytologically document NonSmallCell Lung Cancer ( NSCLC ) SmallCell Lung Cancer ( SCLC ) advance recurrent IIIb IV NSCLC ( adenocarcinoma , squamous cell carcinoma , large cell , mixed otherwise specify ) disseminate recurrent SCLC lung cancer local recurrence . Has documentation progressive disease follow prior chemotherapy refuse receive standard chemotherapy . Has measurable tumor ( least 1 cm unidimensionally ) previously nonirradiated area , previously irradiate area , substantial increase size tumor , base CT scan within 8 week prior enrollment ; tumor previously irradiated area increase 50 % previous minimal diameter AND 8 week radiation .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Advanced recurrent stage IIIb IV non small cell lung cancer</keyword>
	<keyword>Disseminated recurrent small cell lung cancer</keyword>
</DOC>